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Abstract
Background: In metastatic breast cancer (MBC) patients, randomised controlled trials evaluated Bevacizumab as
first-line treatment showed improvements in tumour response rate and progression-free survival (PFS) when added
to chemotherapy. In Morocco, we conducted an observational study to investigate clinical features, treatment and
prognosis associated with Bevacizumab based chemotherapy in first line treatment of HER2 negative MBC.
Findings: Nineteen women were included in this study. All these women were diagnosed as having HER2
negative MBC at the National Institute of Oncology in Rabat, Morocco, between January 2009 and December 2010.
The median age of patients was 48.1 years. Four patients (21%) had metastatic disease at diagnosis and 15 patients
(79%) had received treatment for first metastatic relapse. Bone, liver and lung were the most frequent metastasis
sites. Patients were followed up until April 2011. Most patients had objective response; 15.8% of complete
response, 47.3% of partial response and 21.1% of stabilisation. Median PFS was estimated at 11.5 months. Sub-
groups analysis showed a statistically significant difference (Log-rank test: p = 0.01); PFS for patients receiving
Bevacizumab - weekly Paclitaxel was estimated at 18.1 months, and at 9.1 months for patients receiving the
combination Bevacizumab - Docetaxel. This benefit in PFS was associated with an acceptable safety profile.
Conclusion: As demonstrated in this study, Bevacizumab based chemotherapy in first line treatment of HER2
negative MBC in Morocco and particularly in combination with Taxanes extends PFS, as confirmed in a recent
meta-analysis of 3 randomised controlled phase III studies.
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Background
Metastatic breast cancer (MBC) is rarely cured, and
median survival after the development of metastatic dis-
ease is only 2 to 3 years [1]. Although many chemother-
apeutic agents are available for the treatment of MBC,
the median survival duration has not improved until
very recently.
Numerous studies have demonstrated that angiogen-
esis and in particular VEGF (vascular epidermal growth
factor) over-expression play an essential role in the
growth, progression and metastatic potential of breast
cancer [2-5]. Thereafter, VEGF became a fundamental
target of anti-angiogenic therapy.
Bevacizumab is a humanised recombinant monoclonal
antibody that specifically blocks the binding of VEGF to
high-affinity receptors [6]. In MBC patients, randomised
controlled trials evaluated Bevacizumab as first-line treat-
ment showed improvements in tumour response rate and
progression-free survival (PFS) when added to che-
motherapy [7-9]. However, none of the trials showed sig-
nificant survival benefit. More recently, a meta-analysis
of three randomised, controlled, phase III trials con-
firmed that the addition of Bevacizumab to chemother-
apy regimens provides substantial benefit for women
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but not in overall survival (OS)[10].
The aim of our work is to report histological and ther-
apeutic characteristics, to describe OR and safety profile,
and mainly to analyse PFS of patients treated with Beva-
cizumab-based chemotherapy in first line treatment of
HER2 negative MBC, especially in Moroccan population.
Patients and methods
Clinical data
This is an observational institutional study. We searched
the patient records at the Department of Clinical Oncology,
in the national institute of oncology of Rabat, for the period
from January 2009 to December 2010 for all tumours
coded as HER2 (human epidermal growth factor receptor)
negative MBC. The study respected the ethical rules for
medical research involving human subjects as stipulated by
the WMA Declaration of Helsinki. Our local hospital com-
mittee has approved this study and patients gave their con-
sent. The files of 19 HER2 negative MBC patients treated at
our institution were thoroughly analysed.
All patients had an histologically proven diagnosis of
breast cancer. HER2/neu receptor status was evaluated
using IHC (Immunohistochemistry) or FISH (Fluores-
cence in situ hybridisation). HER2/neu oncoprotein
expression negativity was assessed using the Hercep
Test, scored 0 (absent) or 1+ (weak), and the negativity
of the HER2/neu gene amplification was confirmed by
FISH if score 2+ (moderate) in Hercep Test.
This study had excluded HER2 positive MBC, and all
patients receiving already first line treatment of MBC
with or without Bevacizumab.
Among 19 patients treated for HER2 negative MBC, 4
(21%) had metastatic disease at diagnosis and 15 (79%)
had received treatment for first metastatic relapse (after
a median time of 32.8 months from adjuvant treatment
of localized disease).
Follow up
Patients were followed up until April 2011. All patients
who were not reviewed in the last consultation were
contacted again by telephone.
Assessment of response was performed using RECIST
(Response evaluation criteria in solid tumours) criteria. A
complete response (CR) was defined as the complete disap-
pearance of all evidence of disease. A partial response (PR)
was defined as a reduction of at least 30% of the sum of the
largest diameters of each target lesion, without the appear-
ance of new lesions. Progression was defined as an increase
of at least 20% of the sum of the largest diameters of each
target lesion, or the appearance of one or more new lesions.
Progression-free survival was calculated from the date
of start of treatment until progression or until the date
of last visit.
Statistical analysis
Data was analysed using Win-hospital; an electronic
CRF (case report form). Descriptive statistics with 95%
confidence interval (CI) were calculated according to
standard procedure. Survival curves were constructed
using the Kaplan-Meier method. The log-rank test was
used to compare survival curves. The test was con-
ducted at a 5% significance level.
Findings
The median age of patients was 48.1 years. Infiltrating
ductal carcinoma was the predominant histological sub-
type, and the majority of patients had SBR (Scarff,
Bloom and Richardson) grade II of tumours (47.3%) and
positive hormone receptors (63.1%) (Table 1).
As indicated in Table 2 below, metastasis site was
variable; bone (63.1%), liver (47.3%) and lung (47.3%)
were the most frequent. However, it should be stressed
that percentages in Table 2 do not add up to 100%
because of overlapping
Chemotherapeutic regimens used were different. Seven
patients (36.8%) had received Bevacizumab (10 mg/kg at
day 1 and 15) - Paclitaxel (90 mg/m2 at day 1, 8 and 15)
every 4 weeks, while 7 other patients (36.8%) were treated
with Bevacizumab (15 mg/kg at day 1) - Docetaxel (100
mg/m2 at day 1) every 3 weeks. The combination Bevaci-
zumab (15 mg/kg at day 1) - Paclitaxel (175 mg/m2) every
3 weeks was received by 2 patients (10.5%), and 2 other
patients (10.5%) were treated with Bevacizumab (15 mg/kg
at day 1) - Capecitabine (1000 mg/m2 from day 1 to 14).
Only 1 patient (5.2%) used the protocol Bevacizumab (15
mg/kg at day 1) - Navelbine (25 mg/m2 at day 1 and 8)
The median number of cycles received was 10 cycles
(range 1 to 31)
After a median number of 6 courses of Bevacizumab
based chemotherapy, most patients had an objective
response; 3 patients (15.8%) achieved CR, 9 (47.3%)
achieved PR, and 4 patients (21.1%) obtained stabilisa-
tion with treatment. However for 3 patients (15.8%), the
disease was progressing (Table 3)
Table 1 Clinico-pathological characteristics of patients
Median age 48.1 years
Histological type Infiltrating ductal carcinoma
SBR grade
I 2 (10.5%)
II 9 (47.3%)
III 5 (26.3%)
Not available 3 (15.7%)
Hormone receptors
Positive HR 12 (63.1%)
Negative HR 6 (31.5%)
Not available 1 (5.2%)
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PFS was estimated at 11.5 months. Sub-groups analysis
showed a statistically significant difference (Log-rank
test: p = 0.01); PFS for patients receiving Bevacizumab -
weekly Paclitaxel was estimated at 18.1 months, and at
9.1 months for patients receiving the combination Beva-
cizumab - Docetaxel (Figure 1)
Bevacizumab based chemotherapy was generally well
tolerated (grade 2 hypertension in one patient which
was well managed by medical treatment, and slight epis-
taxis reported by 3 patients). Only one severe toxicity
was noted in one patient, represented by grade 3 bloody
diarrhoea requiring treatment discontinuation (Table 4)
Discussion
Tumour growth and development are dependent on
angiogenesis [11]. Vascular endothelial growth factor
(VEGF) is a key pro-angiogenic mediator, overexpressed
in many tumours and associated with poor prognosis,
making it an attractive target for the development of a bio-
logical therapy [12]. Agents that target angiogenesis, a pro-
cess essential for all types of solid tumour, have the
potential to benefit all breast cancer patients, regardless of
patient and/or disease characteristics. Inhibition of VEGF
signalling has been shown to provide control of tumour
growth and metastasis by causing regression of tumour
vasculature, normalisation of surviving vasculature and
inhibition of further tumour angiogenesis [13,14].
Bevacizumab is a humanised monoclonal antibody
that specifically binds VEGF, preventing it from interact-
ing with receptors on vascular endothelial cells and
thereby inhibiting its pro-angiogenic effects [15,16]. Bev-
acizumab is currently approved for the treatment of
MBC, metastatic colorectal cancer, non-small-cell lung
cancer and renal cell cancer [17,18]. It is also approved
in the United States for the treatment of recurrent glio-
blastoma multiforme [17].
There is preclinical evidence that Taxanes have anti-
angiogenic, as well as cytotoxic, effects, indicating possi-
ble synergies with agents targeting VEGF [19,20]. This
has generated much interest in the combination of anti-
angiogenic biological agents with Taxanes. At present,
Bevacizumab is the most advanced anti-VEGF agent in
development, with clinical data available from three
phase III studies in patients with MBC [7,9,21-23].
E2100 was a phase III trial designed to compare the
efficacy of Bevacizumab plus Paclitaxel with Paclitaxel
alone in the first-line treatment of locally recurrent (LR)
breast cancer or MBC [7,21]. Data from this trial sup-
ported regulatory approval of Bevacizumab plus Pacli-
taxel in Europe and the United States [17,18]. Weekly
Paclitaxel (90 mg/m2, weeks 1-3 every 4 weeks) was
administered to 722 patients, either alone or with Beva-
cizumab (10 mg/kg every 2 weeks). Treatment was con-
tinued until disease progression or unacceptable toxicity.
The combination of Bevacizumab with Paclitaxel signifi-
cantly increased investigator-assessed PFS compared
with Paclitaxel alone [median 11.4 versus 5.8 months;
hazard ratio (HR) = 0.42; P < 0.0001] and had a signifi-
cant effect on objective response rate (ORR) (48% versus
23%, P < 0.0001) [21,24]. A blinded independent review
of tumour assessments in E2100 confirmed the signifi-
cant improvement in PFS (median 11.3 versus 5.8
months; HR = 0.48; P < 0.0001) [21] and ORR (50% ver-
sus 22%, P < 0.0001) [23]. One-year survival was signifi-
cantly higher with Bevacizumab (median 81.4% versus
74%; P = 0.017) and there was a trend towards improved
OS (26.5 versus 24.8 months; HR = 0.87; P = 0.14) com-
pared with Paclitaxel alone [22].
The combination of Bevacizumab with Docetaxel as
first-line therapy for women with LR breast cancer or
MBC was evaluated in the phase III AVastin And DOce-
taxel (AVADO) trial [23]. A total of 736 patients
received Docetaxel (100 mg/m2) in combination with
either Bevacizumab (at 7.5 or 15 mg/kg) or placebo
every 3 weeks. Treatment with Bevacizumab or placebo
was continued until disease progression or unacceptable
toxicity; up to nine cycles of Docetaxel were allowed.
The primary analysis for AVADO was carried out after
a pre-specified number of PFS events and demonstrated
significant PFS improvement in both Bevacizumab arms
relative to placebo [25]. In the latest analysis of data
from this trial, carried out after a median follow-up of
25 months, PFS was superior in both Bevacizumab
treatment arms compared with placebo and results for
t h e1 5m g / k ga r mw e r em o r ef a v o u r a b l et h a nf o rt h e
7.5 mg/kg arm [median 10.0 months (15 mg/kg), HR =
0.67; P = 0.0002 and 9.0 months (7.5 mg/kg), HR =
0.80; P = 0.0450 versus 8.1 months] [23].
Table 2 Metastasis site
Metastasis site Number of patients
Bone 12 (63.1%)
Liver 9 (47.3%)
Lung 9 (47.3%)
Local recurrence 5 (26.3%)
Lymph nods 4 (21%)
Contralateral recurrence 3 (15.7%)
Brain 1 (5.2%)
Table 3 Response assessment to treatment
Response Number of patients
Complete response 3 (15.8%)
Partial response 9 (47.3%)
Stabilisation 4 (21.1%)
Progression 3 (15.8%)
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also demonstrated the efficacy and safety of combining
Bevacizumab with first-line chemotherapy for LR breast
cancer or MBC, including Taxanes [9]. Patients received
placebo or Bevacizumab 15 mg/kg every 3 weeks in
combination with the physician’s choice of Taxanes, an
Anthracycline-based regimen or Capecitabine. Irrespec-
tive of the chemotherapy partner, the combination with
Bevacizumab showed significantly better efficacy than
chemotherapy plus placebo [9].
Recently, a meta-analysis of these three randomised
trials confirmed that the addition of Bevacizumab to
chemotherapy offers a clinically meaningful and statisti-
cally significant improvement in PFS (9.2 vs 6.7 months,
HR = 0.64 and p = 0.0001) and OR in patients with
MBC but does not benefit OS (26.7 vs 26.4 months, HR
= 0.97 and p = 0.56) [10].
The side-effect profile of Bevacizumab is well estab-
lished and generally manageable and is known to differ
considerably from those of conventional chemotherapy
agents [26]. Adverse events associated with Bevacizu-
mab therapy include hypertension, gastrointestinal per-
forations, arterial or venous thromboembolic events,
cardiotoxicity, fistula/abscess, bleeding events, protei-
nuria or wound-healing complications. However, the
more frequently seen adverse events are mild to mod-
erate in severity, responsive to standard treatment
interventions and do not lead to treatment cessation
[18].
In phase III studies, the toxicity profiles of Bevacizu-
mab and Taxanes did not overlap and Bevacizumab -
Taxane doublets were generally well tolerated [7,23].
The improvement in PFS has not been associated with
an OS advantage with the use of Bevacizumab and a
Taxane. Although OS is regarded as a “gold standard”
of efficacy, the availability of other agents to treat
patients with MBC impacts on the difficulty in demon-
strating a significant OS benefit from the initial regimen
used. Overall, these data indicate that since there is no
contraindication or safety issue when combining Bevaci-
zumab with Taxanes, this is a valid treatment option,
with advantages over Taxane doublets.
Despite the small number ofp a t i e n t sc o n s i d e r e di n
our study, results in terms of PFS are similar to pub-
lished literature, with an acceptable safety profile.
Figure 1 Kaplan-Meier curve for patient’s survival.
Table 4 Safety profile
Toxicity Number of patients
Hypertension (grade II) 1(5.2%)
Blood diarrhoea (grade III) 1(5.2%)
Slight epistaxis (grade I) 3(15.8%)
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th November 2011 the
US Food and Drug Administration (FDA) released
news saying that the agency was revoking the it’s
approval of the breast cancer indication for Avastin
(bevacizumab) after concluding that the drug has not
been shown to be safe and effective for that use. It was
also indicated that Avastin will still remain on the
market as an approved treatment for certain types of
colon, lung, kidney and brain cancer (glioblastoma
multiforme).
Conclusion
As demonstrated in this study, Bevacizumab based che-
motherapy and particularly the combination of Bevaci-
zumab and Taxanes confirms the benefice on PFS for
patients who have not received previously cytotoxic
therapy for HER2 negative MBC.
In our opinion, the positive opinion of the Europeen
commission to maintain as treatment option the combi-
nation Bevacizumab - Paclitaxel in first line treatment of
HER2 negative MBC remains therefore valid.
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